|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
New hybrids of 4-amino-2,3-polymethylene-quinoline and p-tolylsulfonamide as dual Inhibitors of acetyl- and butyrylcholinesterase and potential multifunctional agents for Alzheimer’s disease treatmentстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 14 октября 2020 г.
- Авторы: Makhaeva G.F., Kovaleva N.V., Boltneva N.P., Lushchekina S.V., Astakhova T.Yu, Rudakova E.V., Proshin A.N., Serkov I.V., Radchenko E.V., Palyulin V.A., Bachurin S.O., Richardson R.J.
- Журнал: Molecules
- Том: 25
- Номер: 17
- Год издания: 2020
- Издательство: MDPI
- Местоположение издательства: Basel, Switzerland
- Первая страница: 3915
- DOI: 10.3390/molecules25173915
- Аннотация: New hybrid compounds of 4-amino-2,3-polymethylene-quinoline containing different sizes of the aliphatic ring and linked to p-tolylsulfonamide with alkylene spacers of increasing length were synthesized as potential drugs for treatment of Alzheimer’s disease (AD). All compounds were potent inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with selectivity toward BChE. The lead compound 4-methyl-N-(5-(1,2,3,4-tetrahydro-acridin-9-ylamino)-pentyl)-benzenesulfonamide (7h) exhibited an IC50 (AChE) = 0.131 ± 0.01 µM (five times more potent than tacrine), IC50(BChE) = 0.0680 ± 0.0014 µM, and 17.5 ± 1.5% propidium displacement at 20 µM. The compounds possessed low activity against carboxylesterase, indicating a likely absence of unwanted drug-drug interactions in clinical use. Kinetics studies were consistent with mixed-type reversible inhibition of both cholinesterases. Molecular docking demonstrated dual binding sites of the conjugates in AChE and clarified the differences in the structure-activity relationships for AChE and BChE inhibition. The conjugates could bind to the AChE peripheral anionic site and displace propidium, indicating their potential to block AChE-induced β-amyloid aggregation, thereby exerting a disease-modifying effect. All compounds demonstrated low antioxidant activity. Computational ADMET profiles predicted that all compounds would have good intestinal absorption, medium blood-brain barrier permeability, and medium cardiac toxicity risk. Overall, the results indicate that the novel conjugates show promise for further development and optimization as multitarget anti-AD agents.
- Добавил в систему: Радченко Евгений Валерьевич